Genetic epidemiology of glioblastoma multiforme: Confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Song, Wei ^a   Ruder, Avima M ^b   Hu, Liangyuan ^a   Li, Yufeng ^c   Ni, Rong ^c   Shao, Wenshuo ^a   Kaslow, Richard A ^a,c   Butler, Mary Ann ^b   Tang, Jianming ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; LEUKOCYTE ANTIGEN; HLA ANTIGEN;

ADULT; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; GLIOBLASTOMA; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN MOTIF; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; AGED; BRAIN TUMOR; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR GENETICS; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; PROGNOSIS; REGRESSION ANALYSIS; SEQUENCE HOMOLOGY;

ADOLESCENT; ADULT; AGED; ALLELES; BASE SEQUENCE; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GLIOBLASTOMA; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; PROGNOSIS; REGRESSION ANALYSIS; SEQUENCE HOMOLOGY, NUCLEIC ACID; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70349620441     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007157     Document Type: Article

References (61)

1. Davis FG, McCarthy BJ, Berger MS (1999) Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro-oncol 1: 205-211.
2. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, et al. (1999) Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro-oncol 1: 14-25.
3. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, et al. (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225; discussion 226-219.
4. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol 4: 278-299.
5. Aldape KD, Okcu MF, Bondy ML, Wrensch M (2003) Molecular epidemiology of glioblastoma. Cancer J 9: 99-106.
6. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899.
7. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
8. Chen P, Aldape K, Wiencke JK, Kelsey KT, Miike R, et al. (2001) Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res 61: 3949-3954.
9. CBTRUS Standard Statistic Report (2000) Central brain tumor registry of the United States.
10. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, et al. (2008) Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113: 1953-1968.
11. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, et al. (2004) Gene map of the extended human MHC. Nat Rev Genet 5: 889-899.
12. Finn OJ (2008) Cancer immunology. N Engl J Med 358: 2704-2715.
13. Nitta T, Ebato M, Sato K (1994) Association of malignant glioma with the human leukocyte antigen, HLA-A24(9). Neurosurg Rev 17: 211-215.
14. Frigerio S, Ciusani E, Pozzi A, Silvani A, Salmaggi A, et al. (1999) Tumor necrosis factor microsatellite polymorphisms in Italian glioblastoma patients. Cancer Genet Cytogenet 109: 172-174.
15. Machulla HK, Steinborn F, Schaaf A, Heidecke V, Rainov NG (2001) Brain glioma and human leukocyte antigens (HLA)-is there an association. J Neurooncol 52: 253-261.
16. Tang J, Shao W, Dorak MT, Li Y, Miike R, et al. (2005) Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev 14: 2040-2044.
17. Burt RD, Vaughan TL, McKnight B, Davis S, Beckmann AM, et al. (1996) Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States. Cancer Epidemiol Biomarkers Prev 5: 879-887.
18. Goldsmith DB, West TM, Morton R (2002) HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis. Clin Otolaryngol 27: 61-67.
19. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, et al. (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94: 1780-1789.
20. Hildesheim A, Wang SS (2002) Host and viral genetics and risk of cervical cancer: a review. Virus Res 89: 229-240.
21. Matsumoto K, Yasugi T, Nakagawa S, Okubo M, Hirata R, et al. (2003) Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer 106: 919-922.
22. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, et al. (2003) Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 64: 538-542.
23. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, et al. (1994) HLA DRDQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 6: 157-162.
24. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, et al. (2001) Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91: 612-618.
25. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, et al. (2001) Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 94: 711-716.
26. Ruder AM, Waters MA, Carreon T, Butler MA, Davis-King KE, et al. (2006) The Upper Midwest Health Study: a case-control study of primary intracranial gliomas in farm and rural residents. J Agric Saf Health 12: 255-274.
27. Brenner AV, Butler MA, Wang SS, Ruder AM, Rothman N, et al. (2007) Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma. Carcinogenesis 28: 2543-2547.
28. McKenzie LM, Pecon-Slattery J, Carrington M, O'Brien SJ (1999) Taxonomic hierarchy of HLA class I allele sequences. Genes Immun 1: 120-129.
29. Schreuder GM, Hurley CK, Marsh SG, Lau M, Fernandez-Vina MA, et al. (2005) HLA dictionary 2004: summary of HLA-A, -B, -C, -DRB1/3/4/5, - DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Hum Immunol 66: 170-210.
30. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, et al. (2009) Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41: 221-227.
31. Ruder AM, Waters MA, Butler MA, Carreon T, Calvert GM, et al. (2004) Gliomas and farm pesticide exposure in men: the Upper Midwest Health Study. Arch Environ Health 59: 650-657.
32. Bashirova AA, Martin MP, McVicar DW, Carrington M (2006) The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet.
33. Norman PJ, Abi-Rached L, Gendzekhadze K, Korbel D, Gleimer M, et al. (2007) Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet 39: 1092-1099.
34. Kulkarni S, Martin MP, Carrington M (2008) The Yin and Yang of HLA and KIR in human disease. Semin Immunol.
35. Guerini FR, Agliardi C, Zanzottera M, Delbue S, Pagani E, et al. (2006) Human leukocyte antigen distribution analysis in North Italian brain Glioma patients: an association with HLA-DRB1*14. J Neurooncol 77: 213-217.
36. Lampson LA, Hickey WF (1986) Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 136: 4054-4062.
37. Wiendl H, Mitsdoerffer M, Weller M (2003) Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 13: 343-351.
38. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M (2005) HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 64: 523-528.
39. Mittelbronn M, Simon P, Loffler C, Capper D, Bunz B, et al. (2007) Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol 189: 50-58.
40. Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, et al. (2007) Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med 5: 68.
41. Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW (2005) Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 11: 5292-5299.
42. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8: 2851-2855.
43. Jiang X, Lu X, Liu R, Zhang F, Zhao H (2007) Induction of cytotoxic T lymphocytes specific to malignant glioma using T2 cells pulsed with HLA-A2-restricted interleukin-13 receptor alpha 2 peptide in vitro. Acta Biochim Biophys Sin (Shanghai) 39: 641-648.
44. Shimato S, Natsume A, Wakabayashi T, Tsujimura K, Nakahara N, et al. (2008) Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen. J Neurosurg 109: 117-122.
45. Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, et al. (2001) VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol Med 7: 598-608.
46. TCGA C (2008) Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
47. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
48. Wykosky J, Gibo DM, Stanton C, Debinski W (2008) Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 14: 199-208.
49. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 Mutations in gliomas. N Engl J Med 360: 765-773.
50. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, et al. (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62: 1009-1030.
51. Maiers M, Gragert L, Klitz W (2007) High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 68: 779-788.
52. Hughes AL (2002) Natural selection and the diversification of vertebrate immune effectors. Immunol Rev 190: 161-168.
53. Goymer P (2008) Natural selection: The evolution of cancer. Nature 454: 1046-1048.
54. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, et al. (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41: 899-904.
55. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, et al. (2009) Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 41: 905-908.
56. Middleton D, Williams F, Meenagh A, Daar AS, Gorodezky C, et al. (2000) Analysis of the distribution of HLA-A alleles in populations from five continents. Hum Immunol 61: 1048-1052.
57. Shao W, Tang J, Dorak MT, Song W, Lobashevsky E, et al. (2004) Molecular typing of human leukocyte antigen and related polymorphisms following whole genome amplification. Tissue Antigens 64: 286-292.
58. Tang J, Shao W, Yoo YJ, Brill I, Mulenga J, et al. (2008) Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples. J Immunol 181: 2626-2635.
59. L'Haridon M, Paul P, Xerri JG, Dastot H, Dolliger C, et al. (1996) Transcriptional regulation of the MHC class I HLA-A11 promoter by the zinc finger protein ZFX. Nucleic Acids Res 24: 1928-1935.
60. Lefebvre S, Moreau P, Dausset J, Carosella ED, Paul P (1999) Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA. Placenta 20: 293-301.
61. Girdlestone J (2000) Synergistic induction of HLA class I expression by RelA and CIITA. Blood 95: 3804-3808.